Holen Sie sich die Stockscreener-App
2.79
0.00%
0.010
Schlusskurs vom Vortag:
$2.80
Offen:
$2.85
24-Stunden-Volumen:
1.09M
Relative Volume:
0.36
Marktkapitalisierung:
$521.66M
Einnahmen:
$7.25M
Nettoeinkommen (Verlust:
$-17.41M
KGV:
-10.62
EPS:
-0.2627
Netto-Cashflow:
$-38.33M
1W Leistung:
+2.56%
1M Leistung:
-5.41%
6M Leistung:
+114.56%
1J Leistung:
+849.47%
1-Tages-Spanne:
$2.75
$2.855
1-Wochen-Bereich:
$2.70
$2.945
52-Wochen-Spanne:
$0.2701
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.795 | 522.59M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
451.16 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
715.56 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.22 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.24 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
306.33 | 32.84B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Roth Capital | Buy |
| 2025-11-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com India
OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView
Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan
Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan
Epilepsy drug shows favorable safety as Ovid adds pediatric seizure studies - Stock Titan
TradingKey - TradingKey
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Insider Monkey
Ovid Therapeutics (OVID) Eps Diluted (TTM) - Zacks Investment Research
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat
OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan
[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan
OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La
OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà
29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com - Investing.com India
Ovid Therapeutics receives $53.9 million from warrant exercises By Investing.com - Investing.com India
Ovid Therapeutics Boosts Capital Through Warrant Exercises - TipRanks
Ovid Therapeutics receives $53.9 million from warrant exercises - Investing.com
Ovid Therapeutics sees $53.9M gross proceeds as Series A warrants mostly exercised - TradingView
Warrant exercises bring Ovid Therapeutics (NASDAQ: OVID) $53.9M cash - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $5.24 - 富途牛牛
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN) - The Globe and Mail
OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
OVID Reiterated by Wedbush -- Price Target Maintained at $7.00 - GuruFocus
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential - Investing.com
Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ovid Therapeutics Inc-Aktie (OVID) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.75%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):